Background: Chemotherapy-induced peripheral neuropathy (CIPN) can be a debilitating and dose-limiting adverse effect of chemotherapy. Comprehensive self-report tools for CIPN are needed for research and clinical practice.
C hemotherapy-induced peripheral neuropathy (CIPN) is a group of neuromuscular symptoms that result from nerve damage caused by drug therapies used in the treatment of cancer. 1 Peripheral neuropathies are among the most frequently occurring and distressing adverse effects of chemotherapy. 1, 2 More than 30% of patients who receive paclitaxel, docetaxel, bortezomib, thalidomide, or oxaliplatin will develop CIPN. Several other drugs commonly used in the fight against cancer, including capecitabine, cisplatin, interferon !, vinblastine, vinorelbine, and vincristine, cause CIPN in 10% to 29% of patients. 3 The development of new anticancer therapies has led to increased survival, 4 but several of these new therapies are toxic to the nervous system, causing a variety of unpleasant symptoms that are uncomfortable and difficult to manage. 5, 6 Severe peripheral neuropathies may result in dose reductions, a change in chemotherapy regimen, or early cessation of chemotherapy, all of which compromise the success of cancer treatment. 7 In addition, neuropathies can interfere with key aspects of quality of life including physical, social, and role functioning and emotional well-being. 6, 8 The mechanisms that cause CIPN are not well understood. Large-diameter neurons are surrounded by an insulating layer called the myelin sheath. 9 The myelin sheath helps facilitate transmission of impulses along the nerve. Many chemotherapy agents are believed to cause destruction or dysfunction of the myelin sheath. This may cause abnormal burning, prickling, or tingling sensations called paresthesias. Loss of vibratory sense, 2-point discrimination, and proprioception may also result from damage to the myelin sheath. 7 Destruction or dysfunction of C and A-delta fibers results in muscle pain, burning pain in the extremities, and increased sensitivity to cold. Sensitization and hyperexcitability of peripheral nociceptors and hyperexcitability of the dorsal horn may occur. Severe and irreversible sensory neuropathies can be the result of axonal degeneration and injury to the dorsal root ganglion and are associated with neurotoxic chemotherapies such as cisplatin, paclitaxel, and oxaliplatin. 10 Symptoms of CIPN may include numbness and/or tingling beginning in the tips of the fingers or toes; burning, shooting, or electric-like pain; prickling sensation; loss of touch and temperature discrimination; loss of proprioception (knowing where you are in space); and muscle weakness. 5, 10 Symptoms become more pronounced with escalating doses of the drug, frequently resulting in discontinuation of the drug before maximum benefit is achieved. 11 In some cases, particularly in patients receiving oxaliplatin, CIPN symptoms do not develop until after completion of the prescribed amount of chemotherapy. 12 Although symptoms may subside months after the neurotoxic drug is stopped, permanent damage to the nervous system can occur, resulting in long-term symptoms. 10, 13 n Background
Although nerve conduction studies and neurological examination can provide useful objective data, self-report of symptoms is also a critical element of evaluation. Self-report tools have been developed, but many measurement issues exist in the study of CIPN including lack of an ideal assessment technique and lack of attention to the multidimensional characteristics of CIPN.
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Existing self-report tools for CIPN either do not evaluate symptom distress or frequency or do not include detailed evaluation of neuropathic interference with activities.
14Y18 A more comprehensive self-report tool for CIPN will aid researchers in development and evaluation of interventions designed to prevent or decrease neuropathic symptoms.
Peripheral Neuropathy Scale
The Peripheral Neuropathy Scale, the first published assessment tool for CIPN, assessed numbness, tingling, pain, and stiffness and tightness in the hand and feet along with 3 items assessing physical functioning. 8 No evidence of reliability was published at this time, and only content validity data were reported. The items were all worded in the past tense, there was no assessment of motor symptoms, and the tool did not capture the full range of physical limitations experienced by patients with CIPN. 8 The Peripheral Neuropathy Scale was revised by Almadrones and colleagues, 17 who changed the past-tense wording. They also added physical function items and separated the hand and foot items. Additional psychometric testing was conducted. Assessment of motor symptoms, symptom distress, and frequency of symptoms was not included.
Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity Scale
The Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity Scale (FACT/GOG-Ntx) was published by Calhoun and colleagues 19 in 2003. It was designed to evaluate the health-related quality of life of patients with CIPN. It was validated on women receiving carboplatin and paclitaxel. That same year, Cella and colleagues 14 published a taxane version of the FACT/GOG-Ntx with excellent psychometric data. Kopec and colleagues 16 and Huang and colleagues 15 evaluated a version of the scale designed for patients receiving oxaliplatin. Thus, multiple changes to the scale have been made to make it more useful for patients receiving different neurotoxic chemotherapies. Symptom distress and frequency of symptoms are not evaluated, and evaluation of physical function is limited to 4 items including trouble hearing, buttoning buttons, feeling the shape of objects in the hand, and walking.
Research and Treatment of Cancer Quality-of-Life Questionnaire. It measures sensory, motor, and autonomic symptoms and functioning in patients experiencing CIPN. It has been used in several clinical trials, primarily in European countries. The article describing its development was published in 2005 and no further studies describing the reliability and validity of this instrument have been published. Additionally, although this instrument assesses severity of symptoms and interference with activities, it does not assess frequency or symptom distress.
In summary, the 3 self-report tools for CIPN found in a review of the literature are of limited use when a detailed assessment of severity, distress, frequency of peripheral neuropathy, and its impact on usual activities is needed. Therefore, the purpose of this study was to describe the development and evaluate the psychometric properties of a new self-report tool designed to measure CIPN, the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT). Items on the CIPNAT evaluate symptom occurrence, severity, distress, frequency, and interference with daily activities. Psychometric evaluation reported here includes an assessment of content validity, convergent validity, discriminant validity, test-retest reliability, and internal consistency reliability.
n Theoretical Framework
The Theory of Unpleasant Symptoms provided the conceptual framework on which the CIPNAT was developed. 20, 21 Unpleasant symptoms such as CIPN are conceptualized to be multidimensional in nature and suggest that complete assessment should include evaluation of symptom occurrence, severity, distress, and frequency, which are all important aspects of the symptom experience and influence performance status ( Figure 1 ). Severity refers to how severe or intense patients perceive their symptoms. Distress is an emotional component of the symptom experience, signifying how emotionally troubled someone is by his/her symptoms. Frequency refers to how often someone experiences each symptom. Individuals who experience constant or nearly constant symptoms might experience more fatigue, become frustrated, and experience greater physical psychological distress than individuals who rarely experience a symptom. Symptom occurrence, severity, distress, and frequency should be included in the assessment of CIPN because these elements influence physical performance. Neuropathic influence on performance can be assessed by evaluating to what extent the ability to participate in usual activities has been affected by neuropathic symptoms. Thus, the CIPNAT contains items assessing symptom occurrence, severity, distress, and frequency and evaluates physical performance as an outcome.
n Development of the CIPNAT The CIPNAT was developed using information obtained from interviews with 14 persons with CIPN; results are published elsewhere. 22 This is an accepted approach to instrument development used by other researchers. 8 Based on the theoretical framework, symptom experience items assess occurrence, severity, distress, and frequency of neuropathic symptoms identified by at least 33% of patients during interviews. These symptoms included numbness in the hands, numbness in the feet, tingling in the hands, tingling in the feet, sensitivity to cold temperatures, nerve pain, muscle/joint aches, generalized weakness, muscle weakness, and loss of balance. In addition, the physical activities that participants described as being negatively influenced by CIPN were included.
Content validity of the initial draft of the instrument was assessed by a panel of 5 experts including a neurologist, a medical oncologist, 2 doctorally prepared registered nurses, and an oncology certified registered nurse. Members of the panel of experts were selected based on their knowledge and experience with CIPN. Experts were asked to rate individual items for relevance to CIPN. The rating system was as follows: 1 = the item is not relevant to CIPN, 2 = the item is somewhat relevant to CIPN, 3 = the item is quite relevant to CIPN, or 4 = the item is very relevant to CIPN. 23 The experts were also asked to evaluate how comprehensive the CIPNAT was in its approach to evaluation of CIPN and whether items were easy to understand and written at an appropriate-grade level. They were also asked to provide additional comments regarding each item. A content validity index (CVI) was calculated on each item. The CVI is defined as the proportion of items given a rating of quite relevant or very relevant by the experts. Items with a CVI of less than 0.80 were evaluated for replacement or revision. 24 The CVI for the entire instrument was calculated as a mean CVI for all items. The CVIs for individual items ranged from 0.8 to 1.0. The CVI for the entire instrument was 0.95. Comments and suggestions by the experts were also taken into account during initial revisions.
Initial Revisions
Reviewers agreed that the CIPNAT was a comprehensive tool for the assessment of CIPN and recommended minor changes. Items related to muscle or joint aches, nerve pain, and muscle weakness were revised for clarity. Items related to generalized weakness were eliminated because of concerns that generalized weakness was not specific to persons with CIPN. Additional items related to interference with Brelationships,[ Bhobbies or leisure activities,[ and Benjoyment of life[ were added. Minor changes in wording were made to several additional items for the purpose of clarity. Items containing terms that were thought to be Btoo medical[ were also revised. Items that were redundant or not critical to the evaluation of CIPN were eliminated based on feedback from experts that the instrument was too lengthy. The resulting version of the CIPNAT contains a total of 36 items evaluating occurrence, severity, distress, and frequency of 9 neuropathic symptoms and 14 items evaluating neuropathic interference with activities. Included among the interference items were enjoyment of life, sleep, chores, hobbies, walking, exercise, working, picking up objects, writing, holding onto objects, relationships, driving, dressing, and sexual activity.
n Evaluation of Construct Validity and Reliability
Methods
Content validity was ensured by interviewing patients who are experiencing CIPN and by generation of CVIs by a panel of content experts. Following these processes, further validation was needed. Thus, evaluation of construct validity and estimation of reliability of the newly developed and revised tool were undertaken.
Sample and Setting
Patients were recruited from a National Cancer InstituteY designated Comprehensive Cancer Center and a private medical oncology practice in central Florida. All data were collected between August 2008 and October 2008. Eligibility criteria included (1) receiving chemotherapy for a diagnosis of cancer, (2) able to speak and understand English, and (3) between 18 and 90 years of age. Patients were excluded if they had preexisting diabetic neuropathy, known dementia, or psychiatric illness. A convenience sample of 200 outpatients undergoing chemotherapy for cancer were sought for this study. One hundred sixty patients were to have received at least 1 chemotherapy treatment within the last 6 months with drugs of known neurotoxic potential including paclitaxel, docetaxel, cisplatin, or oxaliplatin. A comparison group of 40 neurotoxic chemotherapy-naive patients, who were receiving other types of chemotherapy, was also to be recruited. In total, 167 participants were enrolled (see Results and Table 8 for impact on statistical power and accuracy).
Instruments
Chemotherapy-Induced Peripheral Neuropathy Assessment Tool. The CIPNAT is composed of 2 sets of items: symptom experience items and interference items. Based on the theoretical framework, symptom experience items assess occurrence, severity, distress, and frequency of the 9 neuropathic symptoms identified by patients during interviews. These symptoms include numbness in the hand, numbness in the feet, tingling in the hands, tingling in the feet, sensitivity to cold temperatures, nerve pain, muscle/joint aches, muscle weakness, and loss of balance. Symptom occurrence is assessed first by asking the participant to respond yes or no to whether they have developed each symptom since receiving chemotherapy. BNo[ responses received a score of 0 and Byes[ responses received a score of 1 (range of scores, 0Y9). For each yes response, participants answer additional items evaluating severity, distress, and frequency for each reported symptom using a numeric rating scale of 0 to 10, with higher scores corresponding with more severe, distressing, or frequent symptoms (range of scores, 0Y270). Scores on the group of symptom experience items with occurrence added can range from 0 to 279. Figure 2 shows an example of symptom experience items.
Fourteen interference items assess interference with activities. Activities that are assessed include dressing, walking, picking up objects, holding onto objects, driving, working, participating in hobbies or leisure activities, exercising, sexual activity, sleeping, relationships with other people, writing, usual household chores, and enjoyment of life. Patients answer interference items if they had reported at least 1 of the 9 neuropathic symptoms. Interference with each activity is assessed using a numeric rating scale of 0 to 10. Examples of interference items are illustrated in Figure 3 . Scores on the group of interference items can range from 0 to 140, with higher scores indicating greater interference with activities attributed to neuropathic symptoms.
Nineteen optional descriptive items were included to capture information regarding specific anatomical location of certain symptoms (Figure 2) , time of day when symptoms are most severe, and when in the chemotherapy cycle symptoms are most severe; for example, patients with numbness were asked how far up the hand the numbness extends. The categorical data provide more specific information about patients' experiences and whether they had any injuries as a result of neuropathic symptoms. When injuries had occurred, participants were asked for a description of injuries. These optional items were not included in scoring of the CIPNAT. The method of scoring used in this study is summarized in Table 1 . The Flesch-Kincaid reading level is 3.3, and Flesch Reading Ease is 84.0, indicating that the CIPNAT is easy for adults to read.
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Functional Assessment of Cancer Therapy/Gynecologic Oncology Group. The FACT/GOG-Ntx was used to assess convergent validity of the CIPNAT. The FACT/GOG-Ntx is an 11-item Likert-type scale assessing neuropathic symptoms.
14 Participants are asked to rate the extent to which they agree with given experiences over the past 7 days. Possible responses range from 0 (not at all) to 4 (very much). Higher scores correspond with a higher degree of neuropathic symptoms. Evidence of validity was provided by Calhoun and colleagues, 19 who found significant correlations between the FACT/GOG-Ntx and neurological examination evaluating sensory symptoms, pin sensibility, strength, deep tendon reflexes, vibration sensibility, and nerve conduction. Significant differences in scores from chemotherapynaive individuals and those with known CIPN demonstrated construct validity. Cronbach !'s ranged from .78 to .88. Reliability and validity were also demonstrated in 240 patients receiving paclitaxel and carboplatin for treatment of nonsmall cell lung cancer. This is an appropriate tool to use for assessing convergent validity of the CIPNAT because, although some elements of CIPN thought to be of importance are omitted, the FACT/GOG-Ntx measures the same construct (CIPN) as the CIPNAT.
Demographic Data Form. A demographic data form was developed for this study and included age, sex, race/ethnicity, education, marital status, income, years of formal education, employment status, type of cancer, type of chemotherapy, number of cycles of chemotherapy, and cumulative dose of neurotoxic agent. Information about chemotherapy drugs and doses was obtained by the researcher from the medical record.
Procedures
Approvals from both the Comprehensive Cancer Center Scientific Review Committee and the private practice were obtained. Approval from the University of South Florida institutional review board was obtained. Patients who were appropriate for the study were identified by referring to a list of current patients, which is kept in the nursing station in the infusion centers of the 2 locations. This list described what chemotherapy regimen the patients were receiving that day. Patients who were receiving paclitaxel, docetaxel, oxaliplatin, or cisplatin were approached to determine if they met eligibility criteria and determine their interest in participation. Patients who were receiving nonneurotoxic chemotherapy for any type of cancer were also identified through the list of patients kept in the infusion centers.
Patients were approached by the researcher and informed of study requirements and risks and benefits of taking part in the study. If they agreed to participate, informed consent was obtained. The researcher asked the participants all items on the demographic form that had not been completed using the medical record, the CIPNAT, and FACT/GOG-Ntx and recorded their verbal responses on a questionnaire form. Questionnaires were orally administered at the time of consent while patients were in their private chemotherapy suites. If patients preferred to complete the questionnaires independently, they were permitted to do so. Thirty of the participants on neurotoxic chemotherapy were asked to complete a second CIPNAT for test-retest reliability over the phone at 24 to 72 hours after chemotherapy or in person if they would be coming back to the site during that time. Each patient from the beginning of the study until test-retest data had been collected on 30 participants was asked to complete a second questionnaire. If he/she agreed, he/she was asked for a phone number where he/she could be contacted, and an appointment time for the phone interview was mutually agreed upon. If the researcher was unable to contact the participant at the provided phone number within 7 days of completing the first set of questionnaires, no further attempts to contact that participant were made.
Data Analysis
All data were analyzed using SPSS version 16 (SPSS Inc, Chicago, Illinois). The data were entered into SPSS and examined for dataentry errors using standard data cleaning techniques. Descriptive statistics were analyzed. Evaluating Validity. Validity testing is necessary to ensure that an instrument measures what it is intended to measure, 26 and 3 approaches were used in this study. First, content validity was assessed prior to administering the CIPNAT to patients, and the results of the content validity analysis are previously described. Second, 2 separate techniques were used to evaluate construct validity: discriminant and convergent validity. In discriminant validity approaches, the instrument is administered to 2 groups who might be expected to differ on the characteristic in question. 26 In this case, the instrument was administered to a group of cancer patients at high risk for neuropathic symptoms as well as to a comparison group of cancer patients who were at low risk for neuropathic symptoms. To assess discriminant validity, results on the CIPNAT were compared by use of an independent-group t test to assess whether mean scores of the 2 groups differed significantly. For convergent validity approaches, 2 instruments that purport to measure the same or related constructs are administered to the same group, and the resulting scores are correlated. 26 For this approach, a Pearson correlation coefficient was calculated between scores on the CIPNAT and scores on the FACT/GOG-Ntx. 15 A moderate to high correlation between the CIPNAT and the FACT/GOG-Ntx was expected.
Evaluating Reliability. Reliability for the instrument was evaluated by using the test-retest procedure and Cronbach ! (ie, internal consistency). Neuropathy is conceptualized as relatively stable over a short period for participants actively receiving chemotherapy and for a longer time frame for persons not on chemotherapy. Scores from test to retest are expected to be highly correlated. Patients who were receiving neurotoxic chemotherapy completed the second CIPNAT by telephone approximately 24 to 72 hours after the first set of questionnaires was administered. If the patients were to be returning to the clinic within 24 to 72 hours, the researcher met them there for the purpose of having them complete the second set of questionnaires. Patients who had difficulty writing because of CIPN or preferred to respond verbally had each item read to them with the researcher recording their responses. Because the instrument was designed to measure more than 1 concept, ! levels were determined for the group of symptom experience items, the group of interference items, and for the entire instrument.
n Results
Demographics
There were 127 participants in the group receiving neurotoxic chemotherapy and 40 participants in the comparison group. Eleven participants were from the community practice and 156 participants were from the Comprehensive Cancer Center. Ages ranged from 19 to 80 years, with a mean age of 58 (SD, 11.91) years; 60% of participants were female, and 40% were male; and the majority were married, white, and either retired or disabled (Table 2) . Twenty-seven percent continued to work on a parttime or full-time basis. Participants had a diverse range of incomes and represented varied educational backgrounds. Almost all participants had solid tumors, with breast, lung, or colon cancers being the most frequently occurring sites. Most had stage 3 or 4 disease. From the patients in the group who were on treatment with neurotoxic chemotherapy, approximately 30% were receiving paclitaxel, 31% were receiving docetaxel, 27% were receiving oxaliplatin, and 13% were receiving cisplatin. Participants had received from 1 to 30 treatments, with a mean of 5.2 treatments, and had received an average of 500mg/m 2 of neurotoxic drug. In the group who received neurotoxic chemotherapy, cold sensitivity and muscle/joint aches were the symptoms most often reported when assessed as prevalent (yes/no). Nerve pain was the most severe symptom. Muscle/joint aches were the most distressing symptom. Numbness in the feet was the most frequent symptom (Table 3) . It should be noted that 14.2% of the 127 patients (n = 18) receiving neurotoxic chemotherapy reported no neurotoxic symptoms. Frequencies for the symptom interference items show that neuropathic symptoms interfered with enjoyment of life, sleep, and chores in more than half of participants being treated with neurotoxic chemotherapy. Neuropathic symptoms interfered with walking, exercise, and hobbies in almost 50% of participants (Table 4) . Twentytwo percent (n = 28) had experienced injuries as a result of neuropathic symptoms. The majority of injuries were falls (n = 21) or injuries caused by bumping into things (n = 4). Pulledback muscle (n = 1), poor wound healing (n = 1), and acute hypersensitivity reaction (n = 1) were also reported. Ninety-two percent of patients (n = 23) reporting falls or bumping into things also reported loss of balance.
Validity
Scores on the CIPNAT and the FACT/GOG-Ntx were highly correlated (r = 0.83, P G .001, n = 167), providing strong evidence of convergent validity. Similarly, mean scores on the CIPNAT between cancer patients expected to have symptoms of neurotoxicity and the comparison group were significantly different overall and for the 2 item sets of the CIPNAT (Table 5) . These data provide evidence of discriminant validity.
Reliability
The CIPNAT was administered to a subset of 30 patients for test-retest reliability. Test-retest scores on the total CIPNAT (r = 0.93, P G .001), symptom experience items (r = 0.89, P G .001), and interference items (r = 0.93, P G .001) all showed strong evidence of reliability. In terms of internal consistency, Cronbach ! coefficients were uniformly high for the total CIPNAT (! = .95), the symptom experience items (! = .93), and the interference items (! = .91) ( Table 6 ). Regarding individual items, interference with sexual activity had a low item-to-total correlation (r = 0.25). The remainder of the itemto-total correlations ranged from to 0.38 to 0.70 (Table 7) .
Statistical Power and Accuracy of Psychometric Quantities
The effective sample size and corresponding accuracy achieved in our analysis varied, depending on the type of analysis conducted including correlation between the CIPNAT and the FACT/ GOG-Ntx (ie, convergent validity), independent-group t test comparison of mean scores on the CIPNAT between patients expected to have symptoms of neurotoxicity versus the comparison group (ie, discriminant validity), internal consistency reliability, and test-retest reliability. For all analyses, we sought to have a sufficient sample size to accurately estimate psychometric -quantities. Specifically, unlike some psychometric analyses, factor analyses in particular, that recommend a minimum number of subjects per item, we were principally interested in being able to quantify reliability and validity estimates with a high degree of accuracy (confidence), as expressed by resultant narrow 95% confidence intervals. We fully expected correlation coefficients and reliability coefficients to be significantly different from zero (eg, high Cronbach ! coefficients) and were interested in accurately quantifying these parameters.
With an a priori (planned) sample size of 160 chemotherapy patients, 40 comparison subjects, and 30 of the 160 of the chemotherapy patients selected to undergo test-retest reliability analyses, estimates of variability around the point estimates (ie, accuracy) and statistical power are presented in Table 8 . Because the planned target sample size of 200 participants was not fully achieved, we also present post hoc estimates of accuracy and statistical power based on the final sample size of 127 chemotherapy patients and 40 comparison subjects.
As seen in Table 6 , the quantities Pearson r and Cronbach ! coefficients were estimated with narrow 95% confidence intervals. Similarly, the detectable post hoc effect size of 0.65 with our final sample size of 167 participants is considered Bmedium to large[ and appropriate for assessing discriminate validity. Thus, we believe that our results that have demonstrated both high reliability and validity with the CIPNAT are robust.
n Discussion This is the first study to evaluate the psychometric properties of the CIPNAT and to provide empirical evidence in support of its reliability and validity. The CIPNAT is an instrument for the assessment of CIPN that addresses multidimensional elements including symptom occurrence, severity, distress, frequency, and interference with activities. Test-retest reliability evaluation reveals strong reliability. Internal consistency reliability also indicates that the CIPNAT is reliable and internally consistent. Because the item-to-total correlation for interference with sexual activity was low, this item was deleted from the CIPNAT.
Construct validity evaluations including use of the contrasted groups approach (discriminant validity) and correlation with the FACT/GOG-Ntx (convergent validity) provide excellent evidence of validity for the CIPNAT. Time for completion was no more than 15 minutes, even for those with numerous symptoms, indicating that this may be a useful tool for researchers interested in patients' CIPN symptom experience and the effects of CIPN on performance.
Limitations
A limitation of this study is that patients were predominantly from a large Comprehensive Cancer Center in an urban area. Although this is a tertiary referral center, it serves a distinct geographic region; therefore, the results may not be generalizable to other populations. In addition, although the total sample size was psychometrically adequate, it was not large enough for subgroup analyses. Most notable would be an assessment of the psychometric properties of the CIPNAT by demographic characteristics and individual chemotherapy regimen in particular.
Although patients in this study did not express difficulty completing the CIPNAT, the length may limit its practicality for use in clinical settings; it might need to be completed while patients are waiting to be seen. An abbreviated version of the CIPNAT that does not include the 19 additional items also is being developed and would be easier to use when a detailed description of symptoms is not needed, when time is limited, or participant burden is a concern. It also might be used as a follow-up after a more complete assessment with the CIPNAT. A single study is never sufficient to generate conclusive evidence of validity and reliability; additional psychometric evaluation of the CIPNAT should be conducted, including evaluation of sensitivity to change over time and clinical utility. Use of the CIPNAT may lead to a better understanding of CIPN and help researchers thoroughly evaluate interventions designed to relieve suffering and enhance quality of life for patients with CIPN.
